secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001628280-24-044409
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics reports Q3 2024 revenue $15.4M; net loss narrows to $0.35/share
-------------------------------------------------------------------------------

- Revenue rose to $15.4M (up 39% YoY) driven by an $8M Biogen milestone and $2.9M from Betta license.
- Net loss improved to $24.7M from $27.0M YoY; diluted EPS of -$0.35 vs -$0.55.
- Cash, equivalents and marketable securities $284.4M at Sep 30; expected runway into 2027.
- Cemsidomide Phase 1/2 trial enrolling; MM and NHL data to be presented at ASH Dec 2024.
- Appointed Paige Mahaney as Chief Scientific Officer; delivered second Biogen development candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/0001628280-24-044409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/cccc-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-044409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer